These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 10069766)

  • 21. Low molecular weight heparins: the optimal treatment for venous thromboembolism.
    Daskalopoulos ME; Daskalopoulou SS; Liapis CD
    Curr Med Res Opin; 2004 Jul; 20(7):1001-5. PubMed ID: 15265244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of thromboembolism in the outpatient setting.
    Agnelli G; Rossi R; Santamaria MG
    Semin Hematol; 2000 Jul; 37(3 Suppl 5):23-6. PubMed ID: 11055893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low molecular weight heparins in the long-term treatment of venous thromboembolism.
    Liapis CD; Daskalopoulos ME; Daskalopoulou SE
    J Cardiovasc Surg (Torino); 2002 Aug; 43(4):495-500. PubMed ID: 12124561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism.
    Grau E; Tenias JM; Real E; Medrano J; Ferrer R; Pastor E; Selfa S
    Am J Hematol; 2001 May; 67(1):10-4. PubMed ID: 11279651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of venous thromboembolism: challenging the unfractionated heparin standard.
    Nutescu E; Singh-Khalsa M;
    Pharmacotherapy; 2004 Aug; 24(8 Pt 2):127S-131S. PubMed ID: 15334858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?
    Hull RD; Pineo GF
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():11-23. PubMed ID: 15085462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heparin and low-molecular-weight heparin in the treatment of venous thromboembolism.
    Pineo GF; Hull RD
    Baillieres Clin Haematol; 1998 Sep; 11(3):621-37. PubMed ID: 10331096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low molecular weight versus unfractionated heparin. A clinical and economic appraisal.
    Heaton D; Pearce M
    Pharmacoeconomics; 1995 Aug; 8(2):91-9. PubMed ID: 10155614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis.
    Avritscher EB; Cantor SB; Shih YC; Escalante CP; Rivera E; Elting LS
    Support Care Cancer; 2004 Jul; 12(7):531-6. PubMed ID: 14986076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
    Kamphuisen PW; Agnelli G
    Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
    Prandoni P; Carnovali M; Marchiori A;
    Arch Intern Med; 2004 May; 164(10):1077-83. PubMed ID: 15159264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-molecular-weight heparins in the treatment of deep-vein thrombosis.
    Martineau P; Tawil N
    Ann Pharmacother; 1998 May; 32(5):588-98, 601. PubMed ID: 9606481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outpatient treatment of venous thromboembolism using low molecular weight heparins. An overview.
    Matsagas MI
    Int Angiol; 2004 Dec; 23(4):305-16. PubMed ID: 15767978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery.
    Mismetti P; Laporte S; Darmon JY; Buchmüller A; Decousus H
    Br J Surg; 2001 Jul; 88(7):913-30. PubMed ID: 11442521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
    Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
    Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring.
    Hull RD; Pineo GF; Stein P
    Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of deep vein thrombosis in patients with pulmonary embolism: subgroup analysis on the efficacy and safety of certoparin vs. unfractionated heparin.
    Riess H; Becker LK; Melzer N; Harenberg J
    Blood Coagul Fibrinolysis; 2014 Dec; 25(8):838-44. PubMed ID: 25004024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety profile of different low-molecular weight heparins used at therapeutic dose.
    Gouin-Thibault I; Pautas E; Siguret V
    Drug Saf; 2005; 28(4):333-49. PubMed ID: 15783242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.